Tesofensine + Metoprolol (Tesomet) dosage by bodyweight
Reference dose ranges scaled across bodyweight bands, anchored to the most-cited research dose (500 mcg @ 75 kg). Educational only, never a recommendation.
| Bodyweight band | Reference dose range | At U-100 (1 mg/mL) | Vol. on U-100 (5 mg / 2 mL) | 5× t½ elapsed |
|---|---|---|---|---|
| <60 kg / <132 lb | 312–422 mcg | 0.31–0.42 mL | 13–17 units0.12–0.17 mL | – |
| 60–75 kg / 132–165 lb | 383–518 mcg | 0.38–0.52 mL | 15–21 units0.15–0.21 mL | – |
| 75–90 kg / 165–198 lb | 468–633 mcg | 0.47–0.63 mL | 19–25 units0.19–0.25 mL | – |
| 90–105 kg / 198–231 lb | 553–747 mcg | 0.55–0.75 mL | 22–30 units0.22–0.30 mL | – |
| >105 kg / >231 lb | 638–862 mcg | 0.64–0.86 mL | 26–35 units0.26–0.34 mL | – |
Volume column assumes a standard 5 mg vial reconstituted with 2 mL bacteriostatic water (concentration 2.5 mg/mL); insulin units shown for a U-100 syringe. No published half-life on file for Tesofensine + Metoprolol (Tesomet); the elapsed-time column is hidden.
Tesofensine + Metoprolol (Tesomet) by goal
Read Tesofensine + Metoprolol (Tesomet)'s profile and dosing through a specific research-goal lens.
Dose & PK references
Selected from the Tesofensine + Metoprolol (Tesomet) bibliography for relevance to dosing and pharmacokinetics.
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
- ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
- Trial to Explore Use of Tesofensine Combination in Patients with Hypothalamic Obesity
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.